This is a randomized, split-scar clinical study. After patients undergo the MMS surgery and before the wound is closed one half of the wound edge will be treated with a CO2 laser and the other half will be untreated. The side of the would receiving the laser treatment will be determined by random assignment. The study aims to evaluate if the wound edge that is laser treated will have an improved scar appearance compared to the non-laser treated wound edge.
Age
18–89
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults aged 18-89 years
Diagnosis of cutaneous malignancy treated with MMS
Surgical defect suitable for primary linear or flap closure with adequate length to permit split-scar design
Ability to understand and provide informed consent
You may not be if
Pregnancy
Inability to provide informed consent
Non-English speaking patients
History of abnormal wound healing (e.g., keloid disorder)
Active infection at the surgical site
Immunosuppression felt to significantly impair wound healing
Use of isotretinoin within the past 6 months
Prior radiation therapy to the surgical site
Patients belonging to vulnerable populations including prisoners, children, or individuals unable to consent
Clareo Health | Intraoperative CO₂ (Carbon Dioxide)
